Close
Smartlab Europe
Inizio Ignite

Selventa receives new patent for discovery of biomarker profiles

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Addressing the Boomers: How Pharma Must Adapt Drug Development for the 65+ Demographic

An aging population is reshaping medicine. Why pharma must...

GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services...

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...
- Advertisement -

Selventa, a biomarker discovery company, has received US patent entitled Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems.

The patent is related to methods and techniques that facilitate discovery of biomarkers and aid in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

The patent describes a method of biomarker discovery using a model representative of one or more causative biophysical or biochemical relationships underlying a biological state in a biological system.

A candidate set of biological data is compared against the model to discern a candidate biomarker for the biological state.

A sample received from a patient will be assayed for the presence of the candidate biomarkers to discern a biological state of the patient.

Selventa president and CEO David Graaf said that using the technique, biomarkers may be developed to predict efficacy or toxic effects of a drug.

 

Latest stories

Related stories

Addressing the Boomers: How Pharma Must Adapt Drug Development for the 65+ Demographic

An aging population is reshaping medicine. Why pharma must...

GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services...

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »